Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.80 1.22% 149.90 150.50 150.80 151.20 146.40 146.40 301,731 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 473.2 -126.5 -14.6 - 1,100

Indivior Share Discussion Threads

Showing 3601 to 3624 of 3750 messages
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
DateSubjectAuthorDiscuss
27/11/2020
18:57
Clever RB to wait before acting
buywell3
27/11/2020
18:06
stock should have ben suspended today, pending clarification. absolute shambles
dealy
27/11/2020
18:04
nobody thought about informing Indivior.For it to be withdrawn willy nilly would also raise a lot of questions.
dealy
27/11/2020
17:58
I'm just wondering if this is just kayfabe ? hTtps://prowrestling.fandom.com/wiki/Kayfabe#:~:text=In%20professional%20wrestling%2C%20kayfabe%20(pronounced,part%20of%20a%20wrestling%20storyline. Basically RB and INDV just make a big show of fighting but its to claim from their Insurers or the Advisers who advised on the deals ? Deffo got to be some method to the madness.
the stigologist
27/11/2020
17:37
it almost looks like they put in the claim as a matter of duty (duty to RB shareholders). Probably will be negotiated down but who knows
dealy
27/11/2020
15:55
the motely fool Why did the Indivior share price crash 40% on Friday? Alan Oscroft | Friday, 27th November, 2020 | Drug manufacturer Indivior (LSE: INDV) had been soaring in 2020. In fact, as of market close Thursday, the Indivior share price had more than trebled so far this year. But that came to a crunching halt Friday with a whopping 40% crash. Indivior is still ahead more than 100% year-to-date, but what’s happened? Indivior was spun out of Reckitt Benckiser in 2014. And news emerged Friday that its parent has filed a $1bn lawsuit against it. The claim was, apparently, filed on 13 November. It involves an indemnity agreement between the two companies, signed at the time of their parting. 5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit! According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air… And if you click here we’ll show you something that could be key to unlocking 5G’s full potential... In its announcement, Indivior said: “The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.“ More legal pressure for Indivior So we don’t have the details yet. But it’s telling that Indivior has been facing lawsuits related to its opioid dependency treatment Suboxone. The opioid dependency scandal is huge in the US. But it had seemed the matter was resolved after a previous US court case. On 13 November, Indivior told us that “a United States federal court in the Western District of Virginia has approved the agreement between the group and the U.S. Department of Justice and other government agencies that was announced on July 24. The court has also dismissed all charges that were returned by a grand jury in April 2019.” The company added that it “is pleased to put this matter behind it and move forward in a manner that provides certainty to its business.” That certainty has now been shattered. Thought it was all over? As part of the earlier agreement, Indivior had to pay $600m. Prior to that, in October, former CEO Shaun Thaxter had received a six-month jail sentence on charges relating to misrepresentation of the safety of Suboxone. Reckitt Benckiser had had to stump up $1,4bn to try to put it all behind it. And if that wasn’t enough, Indivior has been trying to fight off generic competitors who claim its patent has expired. That’s quite a story for a FTSE 250 company that, by Friday afternoon at least, has still seen its share price double in 2020. But what now? A tense wait Well, we’ll clearly need to wait and find out the details of the Reckitt Benckiser lawsuit. And how nice of Indivior to release the news on a Friday, to give investors time to stew over the weekend with no real hope of further information. Perhaps obviously, I wouldn’t buy now. But I generally wouldn’t invest in a company that’s been facing big legal problems anyway. And definitely not one connected with the US opioid dependency drama.
waldron
27/11/2020
15:21
Possible remerger
jamesretlaw
27/11/2020
15:10
strong recovery from lows. not a repeat of last year
dealy
27/11/2020
15:05
An indemnity clause hidden in the small print at THE time of the IPO back in 2014 YOU LEGALS OUT THERE Could it be classed out of date or invalid for any other reason as not clearly pointed out to potential shareholders present management could be excused for the oversight perhaps the saga continues
waldron
27/11/2020
14:28
INDV could sure do with some positive newsflow for a change ? Maybe on a potential new blockbuster drug in the pipeline Apropos of nothing the INDV2000 C4X3256 trial study completes December 1st htTps://clinicaltrials.gov/ct2/show/NCT04413552?term=c4x_3256&draw=2&rank=1
the stigologist
27/11/2020
14:22
Who would do business with a Company like RB that tries to kill its own 'children' Talk about low business ethics FFS In any event I doubt this is a terminal blow. Taking on the DoJ is a much tougher battle. This will take years to resolve in the Courts AND should be covered by Insurance ? INDV didn't admit any criminal responsibility themselves in DoJ settlement right ? The CEO took the rap ?
the stigologist
27/11/2020
13:46
tend to agree dealy 27 Nov '20 - 13:42 - 3043 of 3043 0 1 0 the way that is written it sounds like this claim should have been expected
waldron
27/11/2020
13:42
the way that is written it sounds like this claim should have been expected
dealy
27/11/2020
13:30
In the FTSE 250, Indivior was the worst performer, down 45% after the drugmaker said Reckitt Benckiser has submitted a GBP1.07 billion claim to the Commercial Court in London, pursuant to an indemnity from the demerger of Indivior from Reckitt in 2014. Reckitt shares were down 1.0%.
waldron
27/11/2020
12:58
Reading the 9 month results I’m shocked these even went up, the US litigation is far from over once the DOJ are finished, it could go on for years bleeding the company, maybe that’s RandB plan, effectively force administration and take it back legal free
csmwssk12hu
27/11/2020
12:51
Traders in for the small bounce
babbler
27/11/2020
12:35
Why would they wish to kill the company off?That wouldn't get them the £1bn would it?So RB floats off its pharmaceutical division and then post settlements with the D of J strangles it's own creation.Hardly makes sense does it.Actually,this company makes quite useful and valuable products.
steeplejack
27/11/2020
12:28
This is not going to bounce. If anything it will go much further South. They are trying to kill the company off with the damage claim that doubles the MCAP
genierub
27/11/2020
12:17
Trying to bounce
babbler
27/11/2020
12:00
The press will have a field day,two British companies claiming and counter claiming,one the offspring of the other,it's actually pretty lightweight.
steeplejack
27/11/2020
11:57
Perhaps but any case will rumble on for years.It's just that uncertainty will once again stalk the shares.This statement has been put out in a blind panic by all accounts and the market has reacted accordingly.
steeplejack
27/11/2020
11:57
This is a highly unusual move. RB are opening themselves up for litigation here
dealy
27/11/2020
11:56
Last time this fell to 28p from same open area on litigation news. Careful.
babbler
27/11/2020
11:54
They want them back now that US issue is sorted is my take on it.... DL
davidlloyd
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210518 02:01:58